标题
Effective anti-BCMA retreatment in multiple myeloma
作者
关键词
-
出版物
Blood Advances
Volume 5, Issue 15, Pages 3016-3020
出版商
American Society of Hematology
发表日期
2021-08-06
DOI
10.1182/bloodadvances.2021004176
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma
- (2021) Matteo C. Da Vià et al. NATURE MEDICINE
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
- (2021) Nikhil C. Munshi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
- (2021) Mehmet Kemal Samur et al. Nature Communications
- Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)
- (2020) Deepu Madduri et al. BLOOD
- First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial
- (2020) Luciano J. Costa et al. BLOOD
- Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy
- (2020) Jesus G. Berdeja et al. BLOOD
- Anti–B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma
- (2020) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results.
- (2020) Nikhil C. Munshi et al. JOURNAL OF CLINICAL ONCOLOGY
- Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011).
- (2020) Sham Mailankody et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (R/R MM).
- (2020) Saad Zafar Usmani et al. JOURNAL OF CLINICAL ONCOLOGY
- A Real-Time Quantitative PCR Targeting the Viral Vector for the Monitoring of Patients Treated with Axicabtagene Ciloleucel
- (2020) Agathe Baras et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma
- (2019) Adam D. Cohen et al. JOURNAL OF CLINICAL INVESTIGATION
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
- (2019) Noopur Raje et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma
- (2019) Jie Xu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells
- (2019) Haiming Chen et al. LEUKEMIA RESEARCH
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
- (2019) Sagar Lonial et al. LANCET ONCOLOGY
- γ-secretase directly sheds the survival receptor BCMA from plasma cells
- (2015) Sarah A. Laurent et al. Nature Communications
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now